Northwest Biotherapeutics (NWBO) Operating Income Growth (1y) (2011 - 2026)

Northwest Biotherapeutics (NWBO) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 67,132.22 Bn 67,131.94 Bn - -24.89%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.60 Bn 466.80 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.71 Bn 114.46 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 69.83 Bn 61.07 Bn 3.31 Bn 8.65%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 145.20%
9 Alnylam Pharmaceuticals 37.33 Bn 34.32 Bn 959.66 Mn 1,386.07%
10 Northwest Biotherapeutics 274.97 Mn 273.18 Mn - 37.03%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.03%
Dec 31, 2025 27.00%
Sep 30, 2025 3.25%
Jun 30, 2025 15.37%
Mar 31, 2025 -9.95%
Dec 31, 2024 -22.17%
Sep 30, 2024 -7.06%
Jun 30, 2024 -28.63%
Mar 31, 2024 -21.44%
Dec 31, 2023 16.70%
Sep 30, 2023 11.48%
Jun 30, 2023 35.65%
Mar 31, 2023 -5.52%
Dec 31, 2022 -70.27%
Sep 30, 2022 -55.42%
Jun 30, 2022 -70.06%
Mar 31, 2022 37.22%
Dec 31, 2021 54.30%
Sep 30, 2021 79.01%
Jun 30, 2021 -64.64%